[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
← catalyst calendarNCT06229366 · readout ≤ 407 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
142estimated
Sites
7
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-03 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Oligometastatic Prostate Carcinoma
- Hormone Sensitive Prostate Cancer
Interventions
- Drug: [Ac-225]-PSMA-62 (mCRPC)
- Drug: [Ac-225]-PSMA-62 (OmHSPC)
Primary outcomes
what the primary-completion date above is the date OFMaximum tolerated dose (MTD)
measured From first dose of study drug through end of DLT period (4 weeks)
Safety, tolerability, and Recommended Phase II Dose (RP2D)
measured From first dose of study drug through end of treatment (~16 - 24 weeks)
Safety and tolerability
measured From first dose of study drug through end of treatment (~16 - 24 weeks)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed